The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Multiple Myeloma in the Journal for ImmunoTherapy of Cancer on July 12, 2020. SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Multiple Myeloma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for FDA-approved immunotherapies for multiple myeloma, as well as discussion of promising emerging treatment modalities including chimeric antigen receptor T cell therapies and novel monoclonal antibody agents directed against B cell maturation antigen, and patient quality of life issues.
Published July 12, 2020 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma""
SITC is pleased to offer three live, free webinars featuring Expert Panel members from SITC's Multiple Myeloma Immunotherapy Guideline. These educational offerings are designed for healthcare providers who treat cancer patients including oncologists, hematologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants. The live webinars include a dedicated question-and-answer session providing the opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.
In this introductory webinar, Expert Panel members provide attendees with an overview of the published guideline and highlight selected recommendations that are applicable to some of the most common scenarios clinicians may encounter while treating their patients with immunotherapy. After attending this webinar, learners will be better able to implement immunotherapy treatments effectively and in accordance with the recommendations in the SITC CPG. CME, CNE and CPE credits are available.
This advanced webinar is designed for attendees to learn and understand important immune checkpoint inhibitor-related adverse event-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease, among other learning outcomes.
Faculty will engage attendees through a combination of case presentations with a “virtual tumor board” discussion and Q&A with diverse sub-specialty experts based on the needs of each particular case. This high-level webinar is designed so attendees will be able to execute the use of immunotherapy with increased confidence, plan management strategies for difficult cases, and identify and discuss areas of controversy in the immunotherapy field.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com